Lupin has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a rise of 40.42% in its net profit at Rs 316.36 crore for the quarter under review as compared to Rs 225.29 crore for the same quarter in the previous year. However, total income of the company decreased by 4.15% at Rs 2,582.03 crore for Q4FY21 as compared Rs 2,693.79 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 18.15% in its net profit after taxes attributable to owners at Rs 460.36 crore for the quarter under review as compared to Rs 389.63 crore for the same quarter in the previous year. However, total income of the company decreased by 5.25% at Rs 3,841.32 crore for Q4FY21 as compared Rs 4,054.34 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a rise of 72.99% in its net profit at Rs 1258.62 crore as compared to Rs 727.55 crore for the previous year. However, total income of the company decreased by 2.75% at Rs 11,185.02 crore for year under review as compared to Rs 11,500.85 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported net profit after taxes attributable to owners at Rs 1,216.53 crore against net loss of Rs 269.39 crore for the previous year. However, total income of the company decreased by 3.53% at Rs 15,299.25 crore for year under review against net loss of Rs 15,858.52 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |